These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11270922)

  • 21. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness.
    Arango C; Adami H; Sherr JD; Thaker GK; Carpenter WT
    Am J Psychiatry; 1999 Jul; 156(7):1097-9. PubMed ID: 10401460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia.
    Chong SA; Mythily ; Remington G
    Schizophr Res; 2003 Jan; 59(1):67-71. PubMed ID: 12413644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J; Dwolatzky T; Brettholz I; Lerner V
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
    Jeste DV; Lacro JP; Bailey A; Rockwell E; Harris MJ; Caligiuri MP
    J Am Geriatr Soc; 1999 Jun; 47(6):716-9. PubMed ID: 10366172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study.
    Bai YM; Chou KH; Lin CP; Chen IY; Li CT; Yang KC; Chou YH; Su TP
    Schizophr Res; 2009 Apr; 109(1-3):167-81. PubMed ID: 19261444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
    Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
    World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.
    Adelufosi AO; Abayomi O; Ojo TM
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010501. PubMed ID: 25866243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.
    Lohr JB; Cadet JL; Lohr MA; Larson L; Wasli E; Wade L; Hylton R; Vidoni C; Jeste DV; Wyatt RJ
    Schizophr Bull; 1988; 14(2):291-6. PubMed ID: 2904696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.
    Sachdev P; Hume F; Toohey P; Doutney C
    Acta Psychiatr Scand; 1996 Jun; 93(6):451-9. PubMed ID: 8831862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.